ArticleHaematologica2024

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.

Sara Oubari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.